Secondary stroke prevention: inside the vessels and beyond.

Area of Science:

• Neurology
• Pharmacology
• Cardiovascular Medicine

Background:

• Cerebral ischaemic stroke is a chronic, age-dependent condition requiring effective secondary prevention strategies.
• Current prevention primarily uses aspirin (acetylsalicylic acid), with newer agents like ticlopidine and clopidogrel offering marginal benefits.
• Existing prevention paradigms focus on platelet inhibition, but this doesn't fully explain drug efficacy.

Purpose of the Study:

• To review current and alternative hypotheses for secondary stroke prevention.
• To explore mechanisms of action for existing and emerging stroke prevention therapies.
• To highlight the need for understanding neuroprotective properties beyond platelet inhibition.

Main Methods:

• Literature review of current and alternative hypotheses in secondary stroke prevention.
• Analysis of pharmacological and clinical effects of aspirin, ticlopidine, clopidogrel, HMG-CoA reductase inhibitors, and antihypertensives.
• Examination of evidence supporting neuroprotective mechanisms and preconditioning effects.

Main Results:

• Aspirin, ticlopidine, and clopidogrel exhibit neuroprotective properties not explained by platelet inhibition.
• HMG-CoA reductase inhibitors also reduce stroke incidence, independent of lipid-lowering effects.
• A shared neuroprotective mechanism, similar to preconditioning, is evident across these drug classes.

Conclusions:

• Current understanding of secondary stroke prevention requires expansion beyond the platelet inhibition paradigm.
• Neuroprotective and preconditioning effects represent a significant, underappreciated mechanism.
• Further research into these alternative mechanisms could lead to more effective stroke prevention therapies.